Neuronetics Sees Measured Momentum in Q2 2026 as STIM Eyes Profitability Path

In a quarter where the company balances progress with ongoing losses, Neuronetics STIM reported total revenues of $41.6 million for the second quarter of 2026, up 9.1% from the prior year. The Greenbrook segment generated $26.9 million, a 16.8% year-over-year increase. Adjusted EBITDA came in at $0.3 million, reversing a loss of $5.6 million in the same quarter a year ago. Net loss totaled $3.4 million, compared with a $10.1 million loss in Q2 2025. Cash burn in operations and investing combined was $1.4 million, a notable improvement of about $2.3 million versus the prior-year quarter.

As with many early-stage profitability stories, the headline numbers leave room for interpretation. The press release emphasizes progress toward sustained profitability and, more importantly, positive net cash flow from operations and investing. For readers focusing on earnings metrics, the document does not publish an EPS figure or an explicit EPS consensus, so per-share interpretation will hinge on the company’s share count and how investors model the quarterly GAAP loss against non-GAAP adjustments like EBITDA.

Financial highlights and segments

• Total revenue of $41.6 million, up 9.1% year over year.
• Greenbrook revenue of $26.9 million, up 16.8% year over year.
• Adjusted EBITDA of $0.3 million; the company moved from a loss in Q2 2025 to a modest profit on an adjusted basis.
• Net loss of $3.4 million, improved from a $10.1 million loss in the prior-year period.
• Net cash used in operations and investing of $1.4 million, a reduction versus $3.8 million in Q2 2025.

Leadership and strategic moves

The quarter featured notable leadership appointments designed to accelerate the company’s growth trajectory and strengthen governance. Nir Naor was appointed Executive Vice President, Chief Financial Officer, Corporate Secretary, and Treasurer. Cory Anderson was promoted to Executive Vice President/General Manager of Greenbrook clinics, and Rob Greene became Senior Vice President of Sales. The company frames these moves as a way to better align the financing, operations, and sales functions with its national care network and NeuroStar TMS platform.

Management voice and strategic framing

In a tone not unfamiliar to investors who crave clear signaling, CEO Dan Reuvers framed the quarter as “a quarter of real operational progress” toward profitability and a positive cash-flow narrative. He argued that NeuroStar’s potential is being unlocked by expanding access to customers through the Greenbrook clinic network while continuing to tighten operating efficiency. The rhetoric sits in the line of “you can have your technology and a scalable care network, too” — a combination some investors have hoped will translate into steadier free cash flow as the business scales.

What this means for STIM and peers

The balance sheet and cash-flow trajectory are the primary storylines. The improvement in adjusted EBITDA and the reduction in cash burn are positives, but the company remains in a stage where profitability is still a work in progress. The Greenbrook network’s performance will be a key driver to monitor, given its sizable contribution to revenue. If the Greenbrook platform continues to grow without eroding margins, investors may begin to bake a path toward free cash flow into long-horizon valuations.

For the sector, Neuronetics’ approach — pairing a proprietary interventional therapy with a nationwide clinic network — underscores a broader trend: the economics of scale in delivering specialized care can be as important as the technology itself. Competitors and peers watching NeuroStar’s adoption across clinics may consider how to accelerate access, improve utilization, and manage costs through centralized support functions, which could influence margins across the segment.

From an earnings-angle perspective, readers should be mindful of the apparent absence of a formal EPS figure and forward-looking revenue forecast in the press release. In markets where EPS consensus and revenue forecasts drive trading multiple, the absence of per-share metrics and explicit guidance means investors will lean on higher-frequency operational data and cash-flow dynamics to form their own expectations for the stock.

Outlook and questions to watch

• How durable is the Greenbrook revenue growth, and can it sustain a multi-quarter acceleration without pressuring patient mix or reimbursement dynamics?
• Will the shift toward adjusted EBITDA profitability translate into positive, recurring free cash flow in the next few quarters?
• How will new leadership roles influence execution, cross-functional alignment, and sales leverage in a way that meaningfully alters the earnings trajectory?
• What level of visibility will investors gain into EPS and the potential timing of a positive earnings surprise, given the absence of an immediate EPS figure in the press release?
• How will the company’s capital deployment and ongoing investments in the Greenbrook network affect the revenue forecast beyond this quarter?

Conclusion: a quarter with momentum, and questions that stay in the room

Neuronetics’ Q2 2026 results present a case study in the nuanced choreography of growth-stage profitability. Revenue is rising, a national care network is taking shape, and leadership changes are designed to tighten execution. The next few quarters will be telling: can adjusted EBITDA become a reliable bridge to sustainable cash flow, and will the EPS story finally converge with the narrative of a scaled, profitable enterprise? For peers in the interventional therapies space, the emphasis on access, utilization, and cost discipline will likely be a recurring theme as the sector inches toward broader adoption and clearer path to profitability.